Fosaprepitant dimeglumine for the management of chemotherapy-induced nausea and vomiting: patient selection and perspectives
Nellowe Candelario, Marvin Louis Roy Lu Department of Medicine, Einstein Medical Center, Philadelphia, PA, USA Abstract: Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side effect of antineoplastic agents. Several treatment regimens are used to address this problem. Fosap...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-06-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/fosaprepitant-dimeglumine-for-the-management-of-chemotherapy-induced-n-peer-reviewed-article-CMAR |
| _version_ | 1819060223845859328 |
|---|---|
| author | Candelario N Lu MLR |
| author_facet | Candelario N Lu MLR |
| author_sort | Candelario N |
| collection | DOAJ |
| description | Nellowe Candelario, Marvin Louis Roy Lu Department of Medicine, Einstein Medical Center, Philadelphia, PA, USA Abstract: Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side effect of antineoplastic agents. Several treatment regimens are used to address this problem. Fosaprepitant is a neurokinin-1 receptor blocker used in the prevention and treatment of CINV, especially for moderately and severely emetogenic chemotherapy. It is highly effective in the treatment of delayed CINV. Data from previous studies show that fosaprepitant is noninferior to aprepitant in the management of CINV. Fosaprepitant is given as a single-dose intravenous infusion, thus offering better patient compliance. The dose-limiting side effect of fosaprepitant is infusion-related reaction, ranging from pain at the infusion site to thrombophlebitis. This side effect has been reported with coadministration of anthracycline agents. Keywords: chemotherapy nausea and vomiting, fosaprepitant, neurokinin inhibitor |
| first_indexed | 2024-12-21T14:23:35Z |
| format | Article |
| id | doaj.art-f752f7d3306c4640a4eb1875d1e46aef |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-12-21T14:23:35Z |
| publishDate | 2016-06-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-f752f7d3306c4640a4eb1875d1e46aef2022-12-21T19:00:43ZengDove Medical PressCancer Management and Research1179-13222016-06-012016Issue 1778227546Fosaprepitant dimeglumine for the management of chemotherapy-induced nausea and vomiting: patient selection and perspectivesCandelario NLu MLRNellowe Candelario, Marvin Louis Roy Lu Department of Medicine, Einstein Medical Center, Philadelphia, PA, USA Abstract: Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side effect of antineoplastic agents. Several treatment regimens are used to address this problem. Fosaprepitant is a neurokinin-1 receptor blocker used in the prevention and treatment of CINV, especially for moderately and severely emetogenic chemotherapy. It is highly effective in the treatment of delayed CINV. Data from previous studies show that fosaprepitant is noninferior to aprepitant in the management of CINV. Fosaprepitant is given as a single-dose intravenous infusion, thus offering better patient compliance. The dose-limiting side effect of fosaprepitant is infusion-related reaction, ranging from pain at the infusion site to thrombophlebitis. This side effect has been reported with coadministration of anthracycline agents. Keywords: chemotherapy nausea and vomiting, fosaprepitant, neurokinin inhibitorhttps://www.dovepress.com/fosaprepitant-dimeglumine-for-the-management-of-chemotherapy-induced-n-peer-reviewed-article-CMARChemotherapy nausea and vomitingFosaprepitantNeurokinin inhibitor |
| spellingShingle | Candelario N Lu MLR Fosaprepitant dimeglumine for the management of chemotherapy-induced nausea and vomiting: patient selection and perspectives Cancer Management and Research Chemotherapy nausea and vomiting Fosaprepitant Neurokinin inhibitor |
| title | Fosaprepitant dimeglumine for the management of chemotherapy-induced nausea and vomiting: patient selection and perspectives |
| title_full | Fosaprepitant dimeglumine for the management of chemotherapy-induced nausea and vomiting: patient selection and perspectives |
| title_fullStr | Fosaprepitant dimeglumine for the management of chemotherapy-induced nausea and vomiting: patient selection and perspectives |
| title_full_unstemmed | Fosaprepitant dimeglumine for the management of chemotherapy-induced nausea and vomiting: patient selection and perspectives |
| title_short | Fosaprepitant dimeglumine for the management of chemotherapy-induced nausea and vomiting: patient selection and perspectives |
| title_sort | fosaprepitant dimeglumine for the management of chemotherapy induced nausea and vomiting patient selection and perspectives |
| topic | Chemotherapy nausea and vomiting Fosaprepitant Neurokinin inhibitor |
| url | https://www.dovepress.com/fosaprepitant-dimeglumine-for-the-management-of-chemotherapy-induced-n-peer-reviewed-article-CMAR |
| work_keys_str_mv | AT candelarion fosaprepitantdimeglumineforthemanagementofchemotherapyinducednauseaandvomitingpatientselectionandperspectives AT lumlr fosaprepitantdimeglumineforthemanagementofchemotherapyinducednauseaandvomitingpatientselectionandperspectives |